DNA VaccinesMark W. Saltzman, Hong Shen, Janet L. Brandsma Springer Science & Business Media, 2008 M02 2 - 384 pages In the early 1990s, almost 200 yr after Edward Jenner demonstrated the effectiveness of the smallpox vaccine, a new paradigm for vaccination emerged. The conventional method of vaccination required delivery of whole pathogens or structural subunits, but in this new approach, DNA or genetic information was administered to elicit an immunological response. Once it was observed that plasmid DNA delivered in vivo led to production of an encoded transgene (1), two ground-breaking studies demonstrated that immunological responses could be generated against antigenic transgenes via plasmid DNA delivered by DNA vaccination (as this approach is called) (2,3). The appe- ance of this new vaccination strategy coincided with advances in molecular biology, which provided new tools to study and manipulate the basic elements of an organism’s genome and also could also be applied to the design and production of DNA vaccines. DNA Vaccines is a major updated and enhancement of the first edition. It reviews state-of-the-art methods in DNA vaccine technology, with chapters describing DNA vaccine design, delivery systems, adjuvants, current appli- tions, methods of production, and quality control. Consistent with the approach of the Methods in Molecular Medicine series, these chapters contain detailed practical procedures on the latest DNA vaccine technology. The enthusiasm for DNA vaccine technology is made clear by the number of research studies published on this topic since the mid-1990s. |
From inside the book
Results 1-5 of 87
Page 6
... solution is to generate an antibody to the target protein. This can be achieved using a procedure that does not require a polypeptide immunogen. The vaccine gene is fused to a secretory signal (if it does not have one), and ...
... solution is to generate an antibody to the target protein. This can be achieved using a procedure that does not require a polypeptide immunogen. The vaccine gene is fused to a secretory signal (if it does not have one), and ...
Page 26
... solution. The plates are incubated at 37 C for about 14 h. At this time, bacteria clones are visible with naked eyes. The plates should not be incubated at 37 C more than 16 h because the -lactamase (the enzyme responsible for the ...
... solution. The plates are incubated at 37 C for about 14 h. At this time, bacteria clones are visible with naked eyes. The plates should not be incubated at 37 C more than 16 h because the -lactamase (the enzyme responsible for the ...
Page 27
... solution is diluted in 198 L of water by OD and 260 . the To UV in the 260 same absorbance orientation of the [see solution Note filled in a cuvet is recorded 7] and filled with 200 L of (the same cuvet water to set the background ...
... solution is diluted in 198 L of water by OD and 260 . the To UV in the 260 same absorbance orientation of the [see solution Note filled in a cuvet is recorded 7] and filled with 200 L of (the same cuvet water to set the background ...
Page 28
... reaction will guar- antee the homogenous distribution of the components (especially of the en- zyme that is kept in a viscous glycerol solution). The mixture is incubated 2 h at 37 C. The proteins contained in the reaction (the. 28 Pascolo.
... reaction will guar- antee the homogenous distribution of the components (especially of the en- zyme that is kept in a viscous glycerol solution). The mixture is incubated 2 h at 37 C. The proteins contained in the reaction (the. 28 Pascolo.
Page 29
You have reached your viewing limit for this book.
You have reached your viewing limit for this book.
Contents
11 | |
A Stress ProteinFacilitated Antigen Expression System | 41 |
Weiwen Jiang Charles F Reich and David S Pisetsky | 55 |
Delivery of DNA Vaccines Using Electroporation | 73 |
and Methodology | 83 |
Sylvia van Drunen Littelvan den Hurk Shawn Babiuk | 91 |
for DNA Vaccine Delivery | 107 |
Subcellular Trafficking Pathways by Indirect | 127 |
Sandra Scheiblhofer Richard Weiss Maximilian Gabler | 221 |
Immunological Responses of Neonates and Infants | 239 |
DNA Vaccines for Allergy Treatment | 253 |
Protection From Autoimmunity by DNA Vaccination | 269 |
Immune Mechanisms | 281 |
DNA VACCINE PRODUCTION PURIFICATION AND QUALITY | 293 |
Production of Plasmid DNA in Industrial Quantities According | 339 |
LargeScale Nonchromatographic Purification of Plasmid | 351 |
Adjuvant Properties of CpG Oligonucleotides in Primates | 139 |
Complexes of DNA Vaccines With Cationic Antigenic Peptides | 159 |
PrimeBoost Strategies in DNA Vaccines | 171 |
Modifying Professional AntigenPresenting Cells to Enhance | 199 |
Assuring the Quality Safety and Efficacy of DNA Vaccines | 363 |
Index | 375 |
Other editions - View all
Common terms and phrases
acid activation adjuvants antibody antigen antigen-specific APCs approx assay bacterial DNA Biojector buffer cationic CD8+ T cells cellular centrifuge chromatography clinical trials cloning codon coli concentration conjugation containing cover slips CpG motifs CpG ODN culture cytokine delivery dendritic cells detection diluted DL-DNA DNA vaccines electroporation ELISPOT encoding endotoxin enhance enzyme epitopes ethanol expression filter g/mL gene gun genomic human immune responses immunogenicity Immunol immunostimulatory Incubate induce injection Invitrogen lysate lysis macaques medium Methods and Protocols MHC class mice microspheres Molecular molecules mouse mRNA needle-free neonates Note oligodeoxynucleotides oligonucleotides optimal PBMC pDNA pellet peptide plasmid DNA plate PLGA Prepare priming production protein purification Qiagen receptor recombinant Resuspend room temperature RPMI sample sequence serum solution specific sterile stimulation strategies supernatant syringe T-cell T-cell responses target tion tissue transfected tube tumor vector viral virus vitro vivo Wash µg/mL